Status:
COMPLETED
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Prostate Cancer
Cancer of Prostate
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed prostate cancer.
- Prior chemotherapy regimen for prostate cancer
Exclusion
- History of other malignancy in the last 5 years
- Major surgery within the past 21 days
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00257478
End Date
March 1 2007
Last Update
June 7 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuscon, Arizona, United States, 85724
2
Los Angeles, California, United States, 90033
3
Coeur d'Alene, Idaho, United States, 83814
4
New York, New York, United States, 10016